The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen. [electronic resource]

By: Producer: 20140605Description: 87-111, ii-iii p. digitalISSN:
  • 1064-590X
Subject(s): In: Food and drug law journal vol. 69
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.